CN109593702A - A kind of method that engineering strain realizes resting cell synthesis L- phenyllactic acid - Google Patents

A kind of method that engineering strain realizes resting cell synthesis L- phenyllactic acid Download PDF

Info

Publication number
CN109593702A
CN109593702A CN201910044513.5A CN201910044513A CN109593702A CN 109593702 A CN109593702 A CN 109593702A CN 201910044513 A CN201910044513 A CN 201910044513A CN 109593702 A CN109593702 A CN 109593702A
Authority
CN
China
Prior art keywords
ala
gly
val
genetic engineering
phenyllactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910044513.5A
Other languages
Chinese (zh)
Other versions
CN109593702B (en
Inventor
夏雨
茅菁菁
王周平
刘祖河
刘琦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinghua Green Biological Preparation Co ltd
Original Assignee
Jiangnan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangnan University filed Critical Jiangnan University
Priority to CN201910044513.5A priority Critical patent/CN109593702B/en
Publication of CN109593702A publication Critical patent/CN109593702A/en
Application granted granted Critical
Publication of CN109593702B publication Critical patent/CN109593702B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0016—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1)
    • C12N9/0018—Phenylalanine dehydrogenase (1.4.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
    • C12Y104/0102—Phenylalanine dehydrogenase (1.4.1.20)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention discloses a kind of methods that engineering strain realizes resting cell synthesis L- phenyllactic acid, and in particular to one kind is able to achieve co-factor NAD+With the engineering strain of the coexpression Phenylalanine dehydrogenase and L- hydroxy isocaproic acid reductase of NADH self-loopa, the method for synthesizing L- phenyllactic acid by resting cell substrate L-phenylalanine belongs to technical field of bioengineering.L- phenyllactic acid is synthesized with recombinant bacterial strain E.coli BL21 (DE3)/pET28a-pdh-ldh resting cell, and resting cell rate can reach 88.9%~95.6% under the action of adding surfactant.The method achieve co-factor NAD+With the self-loopa of NADH, reduce the additive amount of co-factor, reduce production cost, is combined to L- phenyllactic acid field in industry and has broad application prospects.

Description

A kind of method that engineering strain realizes resting cell synthesis L- phenyllactic acid
Technical field
The present invention relates to a kind of methods that engineering strain realizes resting cell synthesis L- phenyllactic acid, and in particular to one Kind is able to achieve co-factor NAD+With the base of the coexpression Phenylalanine dehydrogenase and L- hydroxy isocaproic acid reductase of NADH self-loopa Because of engineered strain, the method for synthesizing L- phenyllactic acid by resting cell substrate L-phenylalanine belongs to biotechnology neck Domain.
Background technique
L- phenyllactic acid (L-phenyllactic acid, L-PLA), i.e. L-2- hydroxyl -3- phenylpropionic acid are two kinds of hands of PLA Property one of enantiomter, naturally coexist in lactobacillus-fermented product and honey, have with chiral enantiomter D-PLA There is special bioactivity, can be used as chiral intermediate and be widely used in the fields such as chemical industry, medicine, pesticide and biosynthesis.
L-PLA not only has inhibiting effect to a variety of food-borne pathogens, can also inhibit most gram-positive bacteria and The growth of negative bacterium extends the shelf-life of food.L-PLA is small molecular organic acid, and stability is high, and hydrophily is strong, in food and It is easy diffusion in feed, is the metabolite of L-phenylalanine, it is non-toxic to humans and animals cell, have in terms of food antiseptic Very big development potentiality.
The synthesis of L- phenyllactic acid mainly passes through chemical method and bioanalysis, and chemical method synthesis step is complicated, needs using organic Chemical reagent causes certain pollution to environment.In comparison, the bioanalysis of L- phenyllactic acid mild, the work for preparing reaction condition Skill is simple, is not necessarily to chiral resolution.Bioanalysis is also divided into microbe fermentation method, enzyme catalysis method and resting cell method.Microorganism hair Ferment method fermentation time is long, and product needs to separate, complicated for operation.Enzyme catalysis method needs to consume Coenzyme I, at high cost, enzyme purification operation Complexity is not suitable for industrialized production.Resting cell method avoids isolating and purifying for enzyme, provides for enzymic catalytic reaction stable Cellular environment, shorter than transformation time with fermentation method, being combined to L- phenyllactic acid field in industry has very big potentiality.
Currently, using phenylalanine as substrate Synthesis phenyllactic acid, and realize co-factor NAD+With the circulation of NADH, at least It needs the participation of three enzymes, for example synthesizes phenyllactic acid with amino acid deaminase and lactic dehydrogenase transforming phenyl alanine, it need to also be Glucose dehydrogenase is added in system, then co-factor NAD is realized under the action of lactic dehydrogenase and glucose dehydrogenase+With The circulation of NADH.Therefore it provides the L- phenyllactic acid synthesis of a kind of easy to operate, at low cost, high conversion rate, suitable industrialized production Method has important application value for industrially preparing L- phenyllactic acid.
Summary of the invention
The first purpose of the invention is to provide a kind of genetic engineering bacteriums, have co-expressed Phenylalanine dehydrogenase (PheDH) With L- hydroxy isocaproic acid reductase (L-HicDH), amino acid sequence shown in Phenylalanine dehydrogenase ID containing SEQ NO.1, L- Amino acid sequence shown in hydroxy isocaproic acid reductase ID containing SEQ NO.2.
In one embodiment of the invention, with E.coli BL21 (DE3) for host.
In one embodiment of the invention, using pET serial carrier as expression vector.
A second object of the present invention is to provide a kind of methods for constructing said gene engineering bacteria, and encoding phenylalanine is taken off The gene of hydrogen enzyme, the gene for encoding L- hydroxy isocaproic acid reductase are connected with carrier by digestion, are obtained recombinant plasmid, will be recombinated Plasmid is transferred in host cell.
In one embodiment of the invention, the genetic engineering bacterium be E. coli BL21 (DE3)/ PET28a-pdh-ldh is using pET28a as carrier, and building comes from the phenylpropyl alcohol ammonia of bacillus badius (Bacillus badius) Dehydrogenase gene (pdh) and from lactobacillus paracasei (Lactobacillus paracasei) L- hydroxy isocaproic acid also The co-expression plasmid pET28a-pdh-ldh of nitroreductase gene (ldh) is co-expressed after being transformed into E.coli BL21 (DE3) Bacterial strain E.coli BL21 (DE3)/pET28a-pdh-ldh, and realize the two enzymes in the coexpression of Escherichia coli.
In one embodiment of the invention, the gene of encoding phenylalanine dehydrogenase is as shown in SEQ ID NO.3.
In one embodiment of the invention, the gene such as SEQ ID NO.3 institute of L- hydroxy isocaproic acid reductase is encoded Show.
Third object of the present invention is to provide a kind of methods for expressing said gene engineering bacteria, and genetic engineering bacterium is inoculated with To LB liquid medium, 35~38 DEG C, 150~170rpm cultivates 10~14h, as seed liquor；By seed liquor with 1.0%~ 5.0% inoculum concentration is inoculated into LB culture medium, shaken cultivation to OD600Be 0.4~0.6, be added inducer IPTG, 20~25 10~20h is cultivated at DEG C.
Fourth object of the present invention is to provide a kind of method for producing phenyllactic acid, above using L-phenylalanine as substrate The genetic engineering bacterium stated is biocatalyst.
In one embodiment of the invention, reaction condition is 22~26 DEG C, and 200~220rpm reacts 7~15h.
In one embodiment of the invention, the mass ratio of wet thallus and substrate is (3~24): 1.
In one embodiment of the invention, final concentration of 0.005%~0.2% (V/V) is added in reaction system Qula lead to-X-100, final concentration of 0.005%~0.2% (V/V) Tween-20 or final concentration of 0.005%~0.2% (W/V) CTAB.
Fifth object of the present invention is to provide the methods of above-mentioned production phenyllactic acid in chemical industry, pharmacy or biosynthesis field Application.
The plasmid pET28a-pdh- that the present invention passes through building coexpression Phenylalanine dehydrogenase and L- carboxylic acid reductase The plasmid is transferred to Escherichia coli, obtains recombinant bacterial strain E.coli BL21 (DE3)/pET28a-pdh-ldh by ldh.Use recombinant bacterium Strain E.coli BL21 (DE3)/pET28a-pdh-ldh resting cell synthesizes L- phenyllactic acid, 20.0g/L~160.0g/L's The conversion ratio that resting cell synthesizes L- phenyllactic acid is 30.0%~70.0%, is converted under conditions of being added to surfactant Rate can be improved to 89.6%~95.6%.The present invention only need to can solve co-factor NAD using two kinds of enzymes+With the circulation of NADH Problem compared to the type that other inventions for disclosing or having announced reduce enzyme needed for co-factor recycles, and reduces co-factor Additive amount reduces production cost, and being combined to L- phenyllactic acid field in industry has very wide application prospect.
Detailed description of the invention
The building process of Fig. 1: pET28a-pdh-ldh co-expression plasmid.
Fig. 2: the SDS-PAGE figure of full bacterium solution after recombination engineering bacteria inducing expression.
Fig. 3: using L-phenylalanine as the reaction process of substrate Synthesis L- phenyllactic acid.
Fig. 4: the conversion ratio of L- phenyllactic acid under different full cellular density conditions.
Fig. 5: the conversion ratio of L- phenyllactic acid under the conditions of different surfaces activating agent.
Specific embodiment
(1) culture medium
LB culture medium: peptone 10.0g/L, sodium chloride 10.0g/L, yeast powder 5.0g/L.
(2) HPLC measures L- phenyllactic acid content
Column: Sunfire C18；Flow velocity: 1.0mL/min；Temperature: 30 DEG C；Detection wavelength is 254nm；Mobile phase: acetonitrile (buffer solution A contains 0.1% trifluoroacetic acid) and H2O (buffer solution B contains 0.1% trifluoroacetic acid)；Gradient: in 22 minutes from 95.0% water gradient elution to 100.0% acetonitrile.
The building of 1 co-expression plasmid pET28a-pdh-ldh of embodiment
Artificial synthesized Phenylalanine dehydrogenase gene pdh and L- hydroxy isocaproic acid reductase gene ldh.Pcr amplification reaction System (50.0 μ L):ddH235.5 μ L, 5 × Phusion HF Buffer of O 10.0 μ L, dNTPs 1.0 μ L, pdh-up/ldh- Up 1.0 μ L, pdh-down/ldh-down 1.0 μ L, 1.0 μ L, Phusion enzyme of template plasmid, 0.5 μ L.Reaction condition: 1) 98 DEG C Initial denaturation 30s；2) 98 DEG C of denaturation 10s；3) 68 DEG C (pdh)/58.5 DEG C of (ldh) primer annealing 30s；4) 72 DEG C of primer extend 35s (pdh)/50s (ldh) (repeats step 2~4, recycle 30 times)；5) continue to extend 7min for 72 DEG C.PCR product is through Ago-Gel After electrophoresis verifying, impurity is removed with Ago-Gel QIAquick Gel Extraction Kit, target gene after purification is saved backup at 4 DEG C.
The primer of table 1 amplification gene pdh and ldh
Primer Primer sequence
pdh-up 5’-GGGCCCCATATGAGCTTAGTAGAAAAAACATCC-3’
pdh-down 5’-GGGCCCGAATTCTTAGTTGCGAATATCCCATT-3’
ldh-up 5’-GGGCCCGAATTCAAGGAGATATAATGGCACGTAAGATTGGAATTATCGG-3’
ldh-down 5’-GATCCCCTCGAGGAGTGTATCCACAATTTCGTCGA-3’
(2) building (Fig. 1) of pET28a-pdh-ldh co-expression plasmid: using plasmid pET28a as expression vector, building weight Group plasmid pET28a-pdh1.Plasmid pET28a and gene pdh NdeI and EcoRI restriction enzymes double zyme cutting.Digestion system 3.0 5.0 1.0 1.0 μ L of μ L, EcoRI of μ L, NdeI of μ L, pET28a-pdh of (30.0 μ L): 10 × Buffer,ddH2O is complemented to 30.0 μ L, 37 DEG C of water-baths 15min, 80 DEG C of water-bath 5min.
Product T after digestion4DNA ligase connection, obtains recombinant plasmid pET28a-pdh1.Linked system (20.0 μ L): 3.0 μ L, pdh genetic fragment of pET28a 9.0 μ L, 5 × Buffer 4.0 μ L, T41.0 μ L of DNA ligase, sterile water are supplied To 20.0 μ L, 22 DEG C of water-bath 15min, 4 DEG C of ice baths connect overnight.
Connection product is transferred in E.coli DH5 α competent cell, obtained recombinant bacterium is named as E.coli DH5 α/pET28a-pdh1.Pick from the plate transformant single colonie access LB (kanamycins containing 1.0mmol/L) fluid nutrient medium mistake After night culture, after taking out plasmid enzyme restriction, 1.0% agarose gel electrophoresis verifying is carried out, send the bacterium solution after being proved to be successful to sequencing, structure The recombinant plasmid built is named as pET28a-pdh1.
By recombinant plasmid pET28a-pdh1 and gene ldh segment EcoRI and XhoI restriction enzymes double zyme cutting, enzyme 3.0 5.0 1.0 1.0 μ L of μ L, EcoRI of μ L, XhoI of μ L, pET28a-pdh-ldh of system (30.0 μ L): 10 × Buffer is cut,ddH2O complements to 30.0 μ L, 37 DEG C of water-baths 15min, 80 DEG C of water-bath 5min.
Product T after digestion4DNA ligase connection, obtains recombinant plasmid pET28a-pdh-ldh.Linked system 4.0 μ L, ldh genetic fragment of (20.0 μ L): pET28a-pdh1 5.0 μ L, 5 × Buffer 4.0 μ L, T41.0 μ L of DNA ligase, Sterile water complements to 20.0 μ L, 22 DEG C of water-bath 15min, and 4 DEG C of ice baths connect overnight.
Connection product is transferred in E.coli DH5 α competent cell, obtained recombinant bacterium is named as E.coli DH5 α (pET28a-pdh-ldh).Pick from the plate transformant single colonie access LB (kanamycins containing 1.0mmol/L) Liquid Culture After base is incubated overnight, after taking out plasmid enzyme restriction, 1.0% agarose gel electrophoresis verifying is carried out, send the bacterium solution after being proved to be successful to survey The co-expression plasmid of sequence, building is named as pET28a-pdh-ldh.
The building and inducing expression of the coexpression of embodiment 2 bacterial strain E.coli BL21 (DE3)/pET28a-pdh-ldh
After recombinant bacterium E.coli DH5 α/pET28a-pdh-ldh activation culture, plasmid is extracted, by co-expression plasmid PET28a-pdh-ldh is transferred in E.coli BL21 (DE3) competent cell, is E.coli by obtained coexpression Strain Designation BL21(DE3)/pET28a-pdh-ldh。
Coexpression bacterial strain E.coli BL21 (DE3)/pET28a-pdh-ldh is inoculated into LB (that is mould for card containing 1.0mmol/L Element) fluid nutrient medium, 37 DEG C, 160rpm is incubated overnight, as seed liquor.Seed liquor is inoculated into 1.0% inoculum concentration In 100.0mL LB (kanamycins containing 1.0mmol/L) fluid nutrient medium, shaken cultivation to OD600It is 0.6,0.8mmol/L is added Isopropyl-β-D-thiogalactoside (IPTG), cultivate 14h at 22 DEG C.Bacterium solution after culture is at 4 DEG C, 8000rpm, centrifugation 10min removes supernatant, collects thallus.Thallus is spare after twice with 0.85% brine.Bacterium solution SDS-PAGE electrophoresis It identifies (Fig. 2), in which: swimming lane 1, swimming lane 2 be the full bacterium solution not induced, and swimming lane 3 is full bacterium solution after IPTG is induced, two in swimming lane 3 Band size corresponds with Phenylalanine dehydrogenase (PheDH) and L- hydroxy isocaproic acid reductase (L-HicDH) destination protein Size illustrates that two destination proteins successfully realize coexpression in E.coli BL21 (DE3).
Embodiment 3 co-expresses bacterial strain E.coli BL21 (DE3)/pET28a-pdh-ldh resting cell synthesis L- benzene cream Acid
It is divided into two-step reaction by substrate Synthesis L- phenyllactic acid of L-phenylalanine: deamination reaction and reduction reaction (figure 3).Deamination reaction: L-phenylalanine deamination is generated phenylpyruvic acid by Phenylalanine dehydrogenase, meanwhile, along with NAD+To NADH Transformation.Reduction reaction: phenylpyruvic acid is reduced into L- phenyllactic acid by L- hydroxy isocaproic acid reductase, meanwhile, it is arrived along with NADH NAD+Transformation.Therefore, the tandem reaction Synthesis L- benzene of Phenylalanine dehydrogenase and L- hydroxy isocaproic acid reductase is selected Co-factor NAD may be implemented in lactic acid+With the self-loopa of NADH.
Resting cell system (1.0mL): 40.0mmol/L L- phenyllactic acid, 10.0mmol/L NAD+, 20.0~ The full cell of 160.0g/L, 150.0mmol/L Ammonium formate buffer (pH 7.0).For the system at 25 DEG C, 200rpm reacts 12h.So Sample 4000rpm is centrifuged afterwards, takes supernatant, after crossing 0.22 μm of film, carries out HPLC measurement.
(Fig. 4) as the result is shown, abscissa are coexpression bacterial strain E.coli BL21 (DE3)/full cells of pET28a-pdh-ldh Concentration, ordinate is the conversion ratio of L- phenyllactic acid.It is entirely thin to co-express bacterial strain E.coli BL21 (DE3)/pET28a-pdh-ldh Dysuria with lower abdominal colic is combined to L- phenyllactic acid, and the conversion ratio of the resting cell synthesis L- phenyllactic acid of 20.0g/L~160.0g/L is 30.0% ~70.0%.
Different surfactants is added in transformation system: Qula leads to-X-100 (Triton-X-100) (reaction system Final concentration: 0.005%~0.2%V/V), Tween-20 (Tween-20) (reaction system final concentration: 0.005%~0.2%V/V) Or cetyltrimethylammonium bromide (CTAB) (reaction system final concentration: 0.005%~0.2%W/V), using above-mentioned identical item Part, coexpression bacterial strain E.coli BL21 (DE3)/pET28a-pdh-ldh resting cell synthesizes L- phenyllactic acid, with 20.0g/L The conversion ratio of the resting cell synthesis L- phenyllactic acid of~160.0g/L can reach 88.9%~95.6% (Fig. 5).Present invention choosing Two kinds of enzymes can solve co-factor NAD during resting cell+With the circulatory problems of NADH, reduce the addition of co-factor Amount reduces the production cost of L- phenyllactic acid, has very big potentiality in industrialized production L- phenyllactic acid field.
Although the present invention has been described by way of example and in terms of the preferred embodiments, it is not intended to limit the invention, any to be familiar with this skill The people of art can do various change and modification, therefore protection model of the invention without departing from the spirit and scope of the present invention Enclosing subject to the definition of the claims.
SEQUENCE LISTING
<110>Southern Yangtze University
<120>a kind of method that engineering strain realizes resting cell synthesis L- phenyllactic acid
<160> 8
<170> PatentIn version 3.3
<210> 1
<211> 380
<212> PRT
<213> Bacillus badius
<400> 1
Met Ser Leu Val Glu Lys Thr Ser Ile Ile Lys Asp Phe Thr Leu Phe
1 5 10 15
Glu Lys Met Ser Glu His Glu Gln Val Val Phe Cys Asn Asp Pro Ala
20 25 30
Thr Gly Leu Arg Ala Ile Ile Ala Ile His Asp Thr Thr Leu Gly Pro
35 40 45
Ala Leu Gly Gly Cys Arg Met Gln Pro Tyr Asn Ser Val Glu Glu Ala
50 55 60
Leu Glu Asp Ala Leu Arg Leu Ser Lys Gly Met Thr Tyr Lys Cys Ala
65 70 75 80
Ala Ser Asp Val Asp Phe Gly Gly Gly Lys Ala Val Ile Ile Gly Asp
85 90 95
Pro Gln Lys Asp Lys Ser Pro Glu Leu Phe Arg Ala Phe Gly Gln Phe
100 105 110
Val Asp Ser Leu Gly Gly Arg Phe Tyr Thr Gly Thr Asp Met Gly Thr
115 120 125
Asn Met Glu Asp Phe Ile His Ala Met Lys Glu Thr Asn Cys Ile Val
130 135 140
Gly Val Pro Glu Ala Tyr Gly Gly Gly Gly Asp Ser Ser Ile Pro Thr
145 150 155 160
Ala Met Gly Val Leu Tyr Gly Ile Lys Ala Thr Asn Lys Met Leu Phe
165 170 175
Gly Lys Asp Asp Leu Gly Gly Val Thr Tyr Ala Ile Gln Gly Leu Gly
180 185 190
Lys Val Gly Tyr Lys Val Ala Glu Gly Leu Leu Glu Glu Gly Ala His
195 200 205
Leu Phe Val Thr Asp Ile Asn Glu Gln Thr Leu Glu Ala Ile Gln Glu
210 215 220
Lys Ala Lys Thr Thr Ser Gly Ser Val Thr Val Val Ala Ser Asp Glu
225 230 235 240
Ile Tyr Ser Gln Glu Ala Asp Val Phe Val Pro Cys Ala Phe Gly Gly
245 250 255
Val Val Asn Asp Glu Thr Met Lys Gln Phe Lys Val Lys Ala Ile Ala
260 265 270
Gly Ser Ala Asn Asn Gln Leu Leu Thr Glu Asp His Gly Arg His Leu
275 280 285
Ala Asp Lys Gly Ile Leu Tyr Ala Pro Asp Tyr Ile Val Asn Ser Gly
290 295 300
Gly Leu Ile Gln Val Ala Asp Glu Leu Tyr Glu Val Asn Lys Glu Arg
305 310 315 320
Val Leu Ala Lys Thr Lys His Ile Tyr Asp Ala Ile Leu Glu Val Tyr
325 330 335
Gln Gln Ala Glu Leu Asp Gln Ile Thr Thr Met Glu Ala Ala Asn Arg
340 345 350
Met Cys Glu Gln Arg Met Ala Ala Arg Gly Arg Arg Asn Ser Phe Phe
355 360 365
Thr Ser Ser Val Lys Pro Lys Trp Asp Ile Arg Asn
370 375 380
<210> 2
<211> 310
<212> PRT
<213> Lactobacillus paracasei
<400> 2
Met Ala Arg Lys Ile Gly Ile Ile Gly Leu Gly Asn Val Gly Ala Ala
1 5 10 15
Val Ala His Gly Leu Ile Ala Gln Gly Val Ala Asp Asp Tyr Val Phe
20 25 30
Ile Asp Ala Asn Glu Ala Lys Val Lys Ala Asp Gln Ile Asp Phe Gln
35 40 45
Asp Ala Met Ala Asn Leu Glu Ala His Gly Asn Ile Val Ile Asn Asp
50 55 60
Trp Ala Ala Leu Ala Asp Ala Asp Val Val Ile Ser Thr Leu Gly Asn
65 70 75 80
Ile Lys Leu Gln Gln Asp Asn Pro Thr Gly Asp Arg Phe Ala Glu Leu
85 90 95
Lys Phe Thr Ser Ser Met Val Gln Ser Val Gly Thr Asn Leu Lys Glu
100 105 110
Ser Gly Phe His Gly Val Leu Val Val Ile Ser Asn Pro Val Asp Val
115 120 125
Ile Thr Ala Leu Phe Gln His Val Thr Gly Phe Pro Ala His Lys Val
130 135 140
Ile Gly Thr Gly Thr Leu Leu Asp Thr Ala Arg Met Gln Arg Ala Val
145 150 155 160
Gly Glu Ala Phe Asp Leu Asp Pro Arg Ser Val Ser Gly Tyr Asn Leu
165 170 175
Gly Glu His Gly Asn Ser Gln Phe Val Ala Trp Ser Thr Val Arg Val
180 185 190
Met Gly Gln Pro Ile Val Thr Leu Ala Asp Ala Gly Asp Ile Asp Leu
195 200 205
Ala Ala Ile Glu Glu Glu Ala Arg Lys Gly Gly Phe Thr Val Leu Asn
210 215 220
Gly Lys Gly Tyr Thr Ser Tyr Gly Val Ala Thr Ser Ala Ile Arg Ile
225 230 235 240
Ala Lys Ala Val Met Ala Asp Ala His Ala Glu Leu Val Val Ser Asn
245 250 255
Arg Arg Asp Asp Met Gly Met Tyr Leu Ser Tyr Pro Ala Ile Ile Gly
260 265 270
Arg Asp Gly Val Leu Ala Glu Thr Thr Leu Asp Leu Thr Thr Asp Glu
275 280 285
Gln Glu Lys Leu Leu Gln Ser Arg Asp Tyr Ile Gln Gln Arg Phe Asp
290 295 300
Glu Ile Val Asp Thr Leu
305 310
<210> 3
<211> 1143
<212> DNA
<213> Bacillus badius
<400> 3
atgagcttag tagaaaaaac atccatcata aaagatttca ctctttttga aaaaatgtct 60
gaacatgaac aagttgtttt ttgcaacgat ccggcgacag gactaagggc cattatcgct 120
attcatgaca ccacactcgg acctgcgctc ggcggctgcc gcatgcagcc ttataacagt 180
gtggaagaag cattggaaga tgctcttcgc ctttccaaag gaatgactta caaatgcgcg 240
gcgtccgatg tcgactttgg cggcggaaaa gcagtcatta tcggtgatcc gcagaaagat 300
aaatctccag aactgttccg cgcgtttggc caatttgttg attcgcttgg cggccgtttc 360
tatacaggta ctgatatggg aacgaatatg gaagatttca ttcacgccat gaaagaaaca 420
aactgcattg ttggggtgcc ggaagcttac ggcggcggcg gagattcctc tattccaact 480
gccatgggtg tcctgtacgg cattaaagca accaacaaaa tgttgtttgg caaggacgat 540
cttggcggcg tcacttatgc cattcaagga cttggcaaag taggctacaa agtagcggaa 600
gggctgctcg aagaaggtgc tcatttattt gtaacggata ttaacgagca aacgttggag 660
gctatccagg aaaaagcaaa aacaacatcc ggttctgtca cggtagtagc gagcgatgaa 720
atttattccc aggaagccga tgtgttcgtt ccgtgtgcat ttggcggcgt tgttaatgat 780
gaaacgatga agcagttcaa ggtgaaagca atcgccggtt cagccaacaa tcagctgctt 840
acggaggatc acggcagaca ccttgcagac aaaggcattc tgtatgctcc ggattatatt 900
gttaactctg gcggtctgat ccaagtagcc gacgaattgt atgaggtgaa caaagaacgc 960
gtgcttgcga agacgaagca tatttacgac gcaattcttg aagtgtacca gcaagcggaa 1020
ttagatcaaa tcaccacaat ggaagcagcc aacagaatgt gtgagcaaag aatggcggca 1080
agaggccgac gcaacagctt ctttacttct tctgttaagc caaaatggga tattcgcaac 1140
taa 1143
<210> 4
<211> 933
<212> DNA
<213> Lactobacillus paracasei
<400> 4
atggcacgta agattggaat tatcggcctt ggaaacgttg gggctgccgt agcgcacgga 60
ttgattgcac aaggtgtagc cgacgactac gtctttattg atgcaaacga agcaaaggtg 120
aaggctgatc aaattgattt ccaagacgca atggcgaact tggaagcgca cggtaacatt 180
gtgattaacg attgggcagc cttggctgat gctgatgttg tgatttcaac actggggaac 240
atcaagttgc aacaagacaa cccaaccggt gaccgttttg ctgagttgaa gtttaccagc 300
agcatggtgc aatcagtcgg cacaaacttg aaggaatctg gtttccacgg cgtattggtc 360
gtgatttcaa acccggttga cgtgattacg gccttgttcc aacacgtgac tggtttccca 420
gctcacaagg ttatcggaac cggtactttg cttgacacgg cgcgtatgca acgtgcagtt 480
ggtgaggcgt ttgatttgga cccacgttct gtttcaggtt acaacttggg tgagcacggt 540
aactcacaat tcgtagcttg gtcaacggtg cgcgtgatgg gtcaaccaat cgtgacgttg 600
gctgatgccg gcgatattga cttggcggcc atcgaagagg aagcacgtaa gggtggcttc 660
acggtcttga atggtaaggg ctacacgagt tatggtgttg caacgtcagc aatccgcatt 720
gccaaggctg ttatggctga cgcgcatgct gaattggttg tctcaaatcg tcgcgatgac 780
atgggaatgt acttgtcata cccagcgatt attggtcgcg atggtgtctt ggcagaaacg 840
acgcttgatt tgacgacgga tgagcaagaa aagctcttgc aatcacgtga ctacatccaa 900
caacgtttcg acgaaattgt ggatacactc taa 933
<210> 5
<211> 33
<212> DNA
<213>artificial synthesized
<400> 5
gggccccata tgagcttagt agaaaaaaca tcc 33
<210> 6
<211> 32
<212> DNA
<213>artificial synthesized
<400> 6
gggcccgaat tcttagttgc gaatatccca tt 32
<210> 7
<211> 49
<212> DNA
<213>artificial synthesized
<400> 7
gggcccgaat tcaaggagat ataatggcac gtaagattgg aattatcgg 49
<210> 8
<211> 35
<212> DNA
<213>artificial synthesized
<400> 8
gatcccctcg aggagtgtat ccacaatttc gtcga 35

Claims (10)

1. a kind of genetic engineering bacterium, which is characterized in that co-expressed Phenylalanine dehydrogenase and L- hydroxy isocaproic acid reductase, benzene Amino acid sequence shown in alanine dehydrogenase ID containing SEQ NO.1, shown in L- hydroxy isocaproic acid reductase ID containing SEQ NO.2 Amino acid sequence.
2. genetic engineering bacterium as described in claim 1, which is characterized in that with E.coli BL21 (DE3) for host.
3. genetic engineering bacterium as claimed in claim 1 or 2, which is characterized in that using pET serial carrier as expression vector.
4. it is a kind of construct any genetic engineering bacterium of claim 1-3 method, by the gene of encoding phenylalanine dehydrogenase, The gene of coding L- hydroxy isocaproic acid reductase is connected with carrier by digestion, obtains recombinant plasmid, recombinant plasmid is transferred to place In chief cell.
5. a kind of method for expressing any genetic engineering bacterium of claim 1-3, which is characterized in that genetic engineering bacterium to be inoculated with To LB liquid medium, 35~38 DEG C, 150~170rpm cultivates 10~14h, as seed liquor；By seed liquor with 1.0%~ 5.0% inoculum concentration is inoculated into LB culture medium, shaken cultivation to OD600Be 0.4~0.6, be added inducer IPTG, 20-25 DEG C 10~20h of lower culture.
6. a kind of method for producing phenyllactic acid, which is characterized in that using L-phenylalanine as substrate, with any institute of claim 1-3 The genetic engineering bacterium stated is biocatalyst.
7. method as claimed in claim 6, which is characterized in that reaction condition is 22~26 DEG C, 200~220rpm reaction 7~ 15h。
8. method according to claim 6 or 7, which is characterized in that the mass ratio of wet thallus and substrate is (3~24): 1.
9. such as method as claimed in claim 6 to 8, which is characterized in that be added to final concentration of 0.005% in reaction system The Qula of~0.2% (V/V) leads to the Tween-20 or final concentration of of-X-100, final concentration of 0.005%~0.2% (V/V) The CTAB of 0.005%~0.2% (W/V).
10. method described in claim 6-9 is in chemical industry, pharmacy or the application in biosynthesis field.
CN201910044513.5A 2019-01-17 2019-01-17 Method for synthesizing L-phenyllactic acid by whole cell transformation of genetic engineering strain Active CN109593702B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910044513.5A CN109593702B (en) 2019-01-17 2019-01-17 Method for synthesizing L-phenyllactic acid by whole cell transformation of genetic engineering strain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910044513.5A CN109593702B (en) 2019-01-17 2019-01-17 Method for synthesizing L-phenyllactic acid by whole cell transformation of genetic engineering strain

Publications (2)

Publication Number Publication Date
CN109593702A true CN109593702A (en) 2019-04-09
CN109593702B CN109593702B (en) 2020-10-09

Family

ID=65966274

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910044513.5A Active CN109593702B (en) 2019-01-17 2019-01-17 Method for synthesizing L-phenyllactic acid by whole cell transformation of genetic engineering strain

Country Status (1)

Country Link
CN (1) CN109593702B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108841844A (en) * 2018-06-26 2018-11-20 江南大学 A kind of method of efficient production phenylpyruvic acid
CN109517778A (en) * 2018-12-20 2019-03-26 江南大学 A kind of method of bacillus subtilis resting cell phenylalanine production phenyllactic acid
CN113025544A (en) * 2021-03-02 2021-06-25 江南大学 Method for synthesizing L-phenyllactic acid by utilizing recombinant microorganism whole cell catalysis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104130967A (en) * 2014-08-11 2014-11-05 南京林业大学 Escherichia coli with coexpression of L-lactate dehydrogenase and formate dehydrogenase as well as construction method and application of escherichia coli
CN108277190A (en) * 2018-01-18 2018-07-13 江南大学 A kind of method of resting cell phenylalanine production phenyllactic acid
EP3388524A1 (en) * 2017-04-13 2018-10-17 Evonik Degussa GmbH Enzymatic method for producing 2-hydroxy-4-methylmercaptobutanoic acid (mha)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104130967A (en) * 2014-08-11 2014-11-05 南京林业大学 Escherichia coli with coexpression of L-lactate dehydrogenase and formate dehydrogenase as well as construction method and application of escherichia coli
EP3388524A1 (en) * 2017-04-13 2018-10-17 Evonik Degussa GmbH Enzymatic method for producing 2-hydroxy-4-methylmercaptobutanoic acid (mha)
CN108277190A (en) * 2018-01-18 2018-07-13 江南大学 A kind of method of resting cell phenylalanine production phenyllactic acid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHAOJUAN ZHENG 等: "Production of optically pure l-phenyllactic acid by using engineered Escherichia coli coexpressing l-lactate dehydrogenase and formate dehydrogenase", 《JOURNAL OF BIOTECHNOLOGY》 *
茅菁菁 等: "重组大肠杆菌双酶一锅法全细胞合成L-苯乳酸研究", 《中国科技论文在线》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108841844A (en) * 2018-06-26 2018-11-20 江南大学 A kind of method of efficient production phenylpyruvic acid
CN109517778A (en) * 2018-12-20 2019-03-26 江南大学 A kind of method of bacillus subtilis resting cell phenylalanine production phenyllactic acid
CN113025544A (en) * 2021-03-02 2021-06-25 江南大学 Method for synthesizing L-phenyllactic acid by utilizing recombinant microorganism whole cell catalysis

Also Published As

Publication number Publication date
CN109593702B (en) 2020-10-09

Similar Documents

Publication Publication Date Title
US11225675B2 (en) D-lactate dehydrogenase, engineered strain containing D-lactate dehydrogenase and construction method and use of engineered strain
Cui et al. Biotechnological production and applications of microbial phenylalanine ammonia lyase: a recent review
CN110791493B (en) Aspartate ammonia lyase mutant and application thereof
CN108060114B (en) A kind of Escherichia coli of fermenting and producing l-Alanine and its application
CN109593702A (en) A kind of method that engineering strain realizes resting cell synthesis L- phenyllactic acid
CN107937361B (en) A kind of alanine dehydrogenase mutant and its application
CN109055327A (en) Aldehyde Ketoreductase mutant and its application
CN110387379B (en) Mixed culture process and application of recombinant escherichia coli for producing glutathione
CN113969269B (en) D-amino acid oxidase mutant and application thereof in preparation of L-glufosinate
CN108070581B (en) L-aspartate beta-decarboxylase mutant with improved enzyme activity and application thereof
CN110373370B (en) Catalytic system coupled with ATP regeneration system and application of catalytic system in glutathione production process
CN109897845A (en) It is a kind of express thermostable type tyrosine phenol-lyase Escherichia coli and its application
CN113481185A (en) Salt-tolerant beta-galactosidase GalNC2-13 and preparation method and application thereof
CN112210519A (en) Genetically engineered bacterium for secreting acetaldehyde dehydrogenase by using edible fungi
WO2017088095A1 (en) Signal peptide and application thereof in synthesis of l-arginine from conjac powder and value enhancement of conjac powder
CN104673814B (en) A kind of L threonine aldolases for coming from enterobacter cloacae and its application
CN110283797B (en) Tyrosinase, gene, engineering bacterium and preparation method thereof
CN101085984A (en) Low-temperature lipase and its gene sequence
CN113061593B (en) L-malate dehydrogenase mutant and application thereof
CN105985935B (en) A kind of xanthine dehydrogenase truncation body and its application
CN114736881A (en) Glucose oxidase GoxM10 mutant A4D with improved acid stability and derivative mutant and application thereof
CN109097315B (en) Genetically engineered bacterium for high-yield lipopeptide and construction method and application thereof
CN110872595A (en) Acid-resistant expression cassette and application thereof in organic acid production by fermentation
CN115896076B (en) Arginine deiminase mutant, recombinant thereof and application thereof in catalytic production of citrulline
CN114478720B (en) Non-catalytic protein gene for promoting enzymolysis of lignocellulose and non-catalytic protein and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231026

Address after: No. 26 Kaifu Road, Xinghua Economic Development Zone, Taizhou City, Jiangsu Province, 225300

Patentee after: XINGHUA GREEN BIOLOGICAL PREPARATION Co.,Ltd.

Address before: No. 1800 Lihu Avenue, Wuxi City, Jiangsu Province

Patentee before: Jiangnan University